贝伐珠单抗联合化疗对晚期结肠癌患者血清指标水平的影响  

Effect of Bevacizumab combined with chemotherapy on serum indexes in patients with advanced colon cancer

作　　者：彭晓飞[1] 陈凌娟 PENG Xiaofei;CHEN Lingjuan(Department of General Surgery,the Sixth Affiliated Hospital of Guangzhou Medical University,Qingyuan People's Hospi-tal,Guangdong Province,Qingyuan 511518,China;Department of Laboratory,the Sixth Affiliated Hospital of Guangzhou Medical University,Qingyuan People's Hospital,Guangdong Province,Qingyuan 511518,China)

机构地区：[1]广州医科大学附属第六医院清远市人民医院普外科,广东清远511518 [2]广州医科大学附属第六医院清远市人民医院检验科,广东清远511518

出　　处：《中国当代医药》2023年第22期15-18,共4页China Modern Medicine

基　　金：广东省清远市科技计划项目(2022KJJH037)。

摘　　要：目的探讨贝伐珠单抗联合化疗对晚期结肠癌患者血清指标水平的影响。方法选择2018年6月至2022年6月广州医科大学附属第六医院收治的50例晚期结肠癌患者作为研究对象,采用随机数字表法分为对照组和观察组,每组25例。对照组患者采用常规化疗,观察组患者在对照组的基础上加用贝伐珠单抗。比较两组患者的临床治疗效果、癌胚抗原(CEA)、糖类抗原19-9(CA19-9)、糖类抗原242(CA242)、卡氏功能状态(KPS)评分以及不良反应总发生率。结果观察组患者的治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗前,两组患者的CEA、CA19-9、CA242水平比较,差异无统计学意义(P>0.05);治疗后,两组患者的CEA、CA19-9、CA242水平低于本组治疗前,且观察组患者的CEA、CA19-9、CA242水平低于对照组,差异有统计学意义(P<0.05)。治疗前,两组患者的KPS评分比较,差异无统计学意义(P>0.05);治疗后,两组患者的KPS评分高于本组治疗前,且观察组患者的KPS评分高于对照组,差异有统计学意义(P<0.05)。观察组患者的不良反应总发生率低于对照组,差异有统计学意义(P<0.05)。结论晚期结肠癌患者采用贝伐珠单抗联合化疗治疗的效果较好,利于改善患者血清指标,提升患者的功能状态,且能减少不良反应的发生,值得临床广泛应用。Objective To investigate the effect of Bevacizumab combined with chemotherapy on serum indexes in patients with advanced colon cancer.Methods A total of 50 patients with advanced colon cancer admitted to the Sixth Affiliated Hospital of Guangzhou Medical University from June 2018 to June 2022 were selected as the study subjects,they were randomly divided into a control group and an observation group with 25 patients in each group.The patients in the control group were treated with conventional chemotherapy,the patients in the observation group were treated with Bevacizumab on the basis of the control group.The clinical treatment effect,carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9),carbohydrate antigen 242(CA242),Karnovfsky performance status(KPS)score and the total incidence of adverse reactions of the two groups were compared.Results The total effective rate of treatment in the observation group was higher than that in the control group,the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in the levels of CEA,CA19-9 and CA242 of patients between the two groups(P>0.05).After treatment,the levels of CEA,CA19-9 and CA242 of patients in the two groups were lower than those before treatment,the levels of CEA,CA19-9 and CA242 in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).Before treatment,there was no statistically significant difference in KPS score of patients between the two groups(P>0.05).After treatment,the KPS score of patients of the two groups were higher than those before treatment,the KPS score of the observation group was higher than that of the control group,the differences were statistically significant(P<0.05).The total incidence of adverse reactions in the observation group was lower than that in the control group,the difference was statistically significant(P<0.05).Conclusion The combination of Bevacizumab and chemotherapy for patients with adv

关 键 词：晚期结肠癌 贝伐珠单抗 化疗 血清癌胚抗原 糖类抗原 

分 类 号：R735.35[医药卫生—肿瘤]